Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale Director sold 94,378 shares at an average $70.35 ($6,639,523)
  2. 4 Open-market sale COO and Secretary sold 10,000 shares at an average $64.55 ($645,500)
  3. 4 Grant or award Director acquired 2,074 shares (grant or award)
  4. 4 Grant or award Director acquired 2,074 shares (grant or award)
  5. 4 Grant or award Director acquired 2,074 shares (grant or award)
  6. 4 Grant or award Director acquired 2,074 shares (grant or award)
  7. 4 Grant or award Director acquired 2,074 shares (grant or award)
  8. 4 Grant or award Director acquired 2,074 shares (grant or award)
  9. 4 Grant or award Director acquired 2,074 shares (grant or award)
  10. 4 Grant or award Director acquired 2,074 shares (grant or award)
  11. 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
  12. 4 Other disposition Director disposed of 1,000,000 shares (other)
  13. 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
  14. 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
  15. 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
  16. 4 Exercise or conversion Director acquired 3,253 shares (option exercise)
  17. 4 Open-market sale President and CEO sold 18,333 shares at an average $61.40 ($1,125,648)
  18. 4 Open-market sale Director sold 1,666 shares at an average $65.37 ($108,911)
  19. 4 Open-market sale Director sold 46,763 shares at an average $60.11 ($2,811,048)
  20. 4 Open-market sale COO and Secretary sold 10,000 shares at an average $55.49 ($554,864)

Page 12 of 22 · 436 filings